Drugs moving into the clinic: 34
The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
| Sponsor | Name | Indication | Mechanism |
|---|---|---|---|
| Palatin Technologies | PL-3994 | Cardiovascular - acute decompensated congestive heart failure (CHF) | Long acting analog of atrial natriuretic peptide, which is involved in regulation of water and sodium levels in the circulation |
| Arete Therapeutics | AR-9281 | Cardiovascular - hypertension | soluble epoxide hydrolase (s-EH) inhibitor - plays a key role in the cytochrome P450 pathway of arachidonic acid metabolism |
| Avigen | AV411 (ibudilast) | CNS - neuropathic pain | A glial attenuator that suppresses pro-inflammatory cytokines IL-1 beta, TNF alpha, and IL-6, and may upregulate the anti-inflammatory cytokine IL-10 - already approved in Japan |
| Avi Biopharma | AVI-4658 | Duchenne muscular dystrophy (DMD) | Exon Skipping Pre-RNA Interference Technology |
| KeyNeurotek | KN38-7271 | CNS - stroke | cannabinoid receptor agonist |
